Search ARM

Q1 2018 Data Report


This report assembles a global sector overview, including details on financings, partnerships and other deals, clinical trial information, major clinical data events, and ARM’s current legislative and regulatory priorities.

Global Landscape

861+

Regenerative Medicine Companies
Worldwide, Including Gene and
Cell Therapies, and Tissue Engineering
Therapeutic Developers

Financings

Total Q1 2018 Global Financings

Total Global Financing

$3.8 Billion

135%

Increase from Q1 2017

Gene & Gene-modified
Cell Therapy

$3.1 Billion

248%

Increase from Q1 2017

Cell Therapy

$1.9 Billion

42%

Increase from Q1 2017

Tissue Engineering

$363.1 Million

1,347%

Increase from Q1 2017

Total Global Financings by Type, by Year

959

Clinical trials underway
worldwide by the end of Q1 2018

PH. 1

320

PH. 2

549

PH. 3

90

Clinical Trials

Number of Clinical Trials Utilizing Specific
RM / AT Technology:

Q1 2018

Gene Therapy
Gene-Modified
Cell Therapy
Cell Therapy
Tissue Engineering

Clinical Trials by Indication: Q1 2018

Report Infographics